
Giant, Glowing Gas Cloud Discovered Just 300 Light-Years Away
Stars form from collapsing clouds of molecular gas. We see this in the likes of the Orion Nebula, which gets energized by hot ultraviolet radiation of the young stars born within. However, finding molecular clouds before they begin producing stars is more difficult.
Such clouds are predominantly made from molecular hydrogen gas, which, when it isn't being energized by starlight, is very faint — almost invisible. (Atomic hydrogen, on the other hand, is easily detectable by radio telescopes). Astronomers usually use radio telescopes to detect carbon monoxide, which is available in much lower quantities in molecular clouds, as a proxy.
On supporting science journalism
If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.
But what about the clouds without much carbon monoxide?
Astronomers led by Blakesley Burkhart of Rutgers University–New Brunswick in New Jersey and Thavisha Dharmawardena of New York University, have pioneered an entirely new way of seeing the invisible. Using far-ultraviolet data from the Korean STSAT-1 satellite, they directly detected molecules of hydrogen fluorescing.
"This is the first-ever molecular cloud discovered by looking for far-ultraviolet emission of molecular hydrogen directly," Burkhart said in a statement. "This cloud is literally glowing in the dark."
The cloud is roughly crescent-shaped and sits on the edge of the Local Bubble, which is a volume of space where the interstellar medium is more rarefied than its surroundings, perhaps having been emptied by the shockwaves of hundreds of ancient supernovas. The sun and our solar system are passing through the Local Bubble, and have been doing so for the past five million years or so.
The cloud, named Eos after the goddess of Greek mythology who signified the dawn, contains approximately 3,400 solar masses worth of gas. It's also depleted in carbon monoxide, which is why it had gone undetected by conventional means.
Eos is predicted to disperse, or photodissociate, as a result of background photons impacting the cloud's molecules, in about 5.7 million years' time. This is too soon for it to begin forming stars, unless there is some other trigger that advances things, such as the gravitational disturbance of another passing cloud. Intriguingly, the average star-formation rate in our sun's neighborhood has been calculated at 200 solar masses per million years. Eos is losing mass to the wider interstellar medium at a rate of 600 solar masses per million years, three times the rate at which molecular gas is converted into stars. Therefore, this dispersion of molecular clouds as a result of photodissociation from light emitted by nearby stars seems to act as a feedback mechanism to regulate the rate of star formation, Burkhart's team believes. This is useful information for telling us more about the conditions needed to enable star formation in other, more distant clouds.
"When we look through our telescopes, we catch whole solar systems in the act of forming, but we don't know in detail how that happens," said Burkhart. "Our discovery of Eos is exciting because we can now directly measure how molecular clouds are forming and dissociating, and how a galaxy begins to transform interstellar gas and dust into stars and planets."
And the discovery of other, similar clouds could be just on the horizon.
"The use of the far-ultraviolet fluorescence emission technique could rewrite our understanding of the interstellar medium, uncovering hidden clouds across the galaxy and even out to the furthest detectable limits of cosmic dawn," said Dharmawardena.
Eos may not see the dawn of new stars, but its existence is testament to a greater dawn, going all the way back to near the beginning of the universe, in which stars have brought daylight to a dark cosmos.
The findings were published on April 28 in the journal Nature Astronomy.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
HoneyNaps Launches Cloud Version of AI Sleep Diagnostic Software "SOMNUM™" at SLEEP 2025
HIPAA-compliant cloud-based service provides diagnostic reports via the web with no installation required AI-powered trial service offered, highlighting potential for hospital-specific integration Presented performance of heart rate-based sleep stage estimation algorithm through oral and poster presentations BOSTON, Aug. 19, 2025 /PRNewswire/ -- HoneyNaps, a medical AI diagnostics company, showcased both its technological capabilities and research achievements at SLEEP 2025, the world's largest sleep medicine conference held in Seattle, USA, from June 8 to 11. SLEEP 2025 is a prestigious international conference co-hosted by the American Academy of Sleep Medicine (AASM) and the Sleep Research Society (SRS), drawing approximately 5,000 sleep professionals and featuring over 1,000 of the latest research presentations. HoneyNaps has been the only Korean company to participate in the conference for four consecutive years since 2022. At this year's conference, the company further reinforced its academic credibility through both oral and poster presentations. Notably, in an oral presentation titled "Development and Evaluation of an Exclusively ECG-based Deep Learning Model for Sleep Staging," the company introduced a deep learning model that reliably classifies sleep stages using single-lead ECG signals, demonstrating significantly improved accuracy over conventional methods. At its exhibition booth, HoneyNaps drew attention by unveiling SOMNUM™ Cloud, an AI solution for automated analysis of polysomnography (PSG) data. Users can upload EDF files extracted from PSG devices to the cloud, where the AI engine automatically analyzes the data and generates a comprehensive report — easily downloadable online with no software installation required. During the conference, HoneyNaps offered a free trial consisting of three AI analyses, enabling visitors to experience SOMNUM Cloud in a clinical-like setting. The hands-on program was met with enthusiastic feedback from U.S. sleep physicians and RPSGTs (Registered Polysomnographic Technologists). Taekyoung (Sean) Ha, PhD, President of HoneyNaps USA, stated, "With its cloud-based architecture, streamlined implementation process, and HIPAA compliance, more than 100 U.S. medical institutions expressed interest in potential adoption. We also held individual meetings with leading global sleep companies to discuss potential strategic collaborations". For further information, please contact:HoneyNaps USA, Kwon / Managing DirectorEmail: sleep@ #517, SPACES, 361 Newbury Street, Boston, MA, 02115Website: View original content to download multimedia: SOURCE HoneyNaps Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
Landmark Science announces research to be presented at ISPE 2025
At this year's conference, Landmark Science spotlights real-world evidence's power to drive GLP-1 and Wegovy insights in Medicare and shape regulatory decision-making. LOS ANGELES, Aug. 19, 2025 /PRNewswire/ -- Landmark Science today announced its presence at International Society for Pharmacoepidemiology (ISPE) 2025 annual conference, in collaboration with Innovaccer, set to take place August 22–26 in Washington D.C. Landmark Science's real-world data is featured across five pieces of research to be presented at the conference. The research provides a timely look into patient populations initiating GLP-1 receptor agonists (RAs), offering new insights into the characteristics of Medicare patients initiating these therapies. They also offer a special focus on Medicaid patients initiating Wegovy (semaglutide) for cardiometabolic and cardiovascular risk reduction — an area of growing importance as GLP-1 RAs expand beyond diabetes management. "GLP-1s are on the rise in Medicare — from Type 2 diabetes and obesity to cardiovascular risk reduction, kidney disease, obstructive sleep apnea, and noncirrhotic MASH, indications for GLP-1s have expanded fast. But not a lot is known about utilization in a Medicare population. Real-world evidence is essential in understanding prescribing patterns, patient outcomes, and safety profiles, ultimately guiding optimal care strategies and policy decisions for Medicare beneficiaries," said Shivani Aggarwal, CEO. "The rapid adoption of GLP-1s like semaglutide in cardiometabolic care highlights a critical need for real-world data to inform access, outcomes, and equity," said Puneet Budhiraja - Vice President, Analytics at Humbi AI by Innovaccer. "At ISPE, we're excited to share data that helps stakeholders better understand who is initiating these therapies — and who might be left behind." At this year's ISPE, Landmark epidemiologists are also generating novel methodologies that will shape the future of evidence generation used to support regulatory decision-making. "Our research uncovers nuanced trends and synthesizes them into transparent, evidenced based research—to showcase and drive the utility of real-world evidence in regulatory decision-making," said Shivani Aggarwal. Highlights include: Two poster presentations on Medicare beneficiaries initiating GLP-1 RAs and Wegovy. Two poster presentations underscoring RWE's potential for use in regulatory decision-making. A poster presentation introducing a framework operationalizing regulatory guidelines into key steps for submission success. Schedule a meeting with Landmark Science at ISPE 2025, and learn more about our abstracts and events, including workshops and panels. Follow Landmark Science on LinkedIn for more updates from #ISPE2025. Poster Discussions and Presentations Characteristics of Patients Initiating Glucagon-like Peptide-1 (GLP-1) Receptor Agonists (RAs) for Cardiometabolic Risk Reduction in a Medicare Population This study analyzes patient demographics, comorbidities, and outcomes among Medicare beneficiaries initiating any GLP-1 RAs, shedding light on the populations adopting these treatments. - Monday Aug 25, 2025 | Hall D | Poster Session B: 11:30 AM- 1:00 PM- Poster Code: B-032 Characteristics of Patients Initiating Wegovy (Semaglutide) for Cardiovascular Risk Reduction in a Medicare Population Focusing specifically on Wegovy, this analysis offers a more granular view into who Wegovy initiators are, how they responded, and what happened after Wegovy became an option for cardiovascular protection. - Monday Aug 25, 2025 | Hall D | Poster Session B: 11:30 AM- 1:00 PM- Poster Code: B-033 Characteristics of RWE used in Regulatory Decision-Making for Marketing Authorization Applications (MAAs) Real-world evidence use is growing but still has mixed acceptance. Here we synthesize emerging patterns into actionable insights for success. - Monday Aug 25, 2025 | Hall D | Poster Session B: 11:30 AM- 1:00 PM- Poster Code: B-079 Evaluation of Real-World Evidence in Regulatory and HTA Submissions Real-world evidence isn't judged the same everywhere — and the differences matter. We review feedback from regulatory and key HTA bodies to describe the acceptability of RWE in marketing applications. - Monday Aug 25, 2025 | Hall D | Poster Session B: 11:30 AM- 1:00 PM- Poster Code: B-080 Framework for Real-World Data Used in Regulatory Submissions Discover our framework, which operationalizes regulatory guidelines about real-world data into key steps for submission readiness. - Tuesday Aug 26, 2025 | Hall D | Poster Session C: 12:00 PM – 1:30 PM- Poster Code: C-124 About Landmark Science, Science, Inc. is a premier life science research organization providing real-world evidence and health outcomes research solutions. The company provides a comprehensive suite of services enabling the use of RWE to help patients. Landmark Science's team of experts deliver RWE for clinical program strategy, health economics, commercial, market access, regulators, and payors to meet diverse needs efficiently. Specialties include complex study designs used to support regulatory submissions, therapeutic area expertise, and data landscaping. To learn more, please visit or contact info@ Media Contact:Landmark Sciencemedia@ (424) 535-3011https:// View original content to download multimedia: SOURCE Landmark Science, Inc
Yahoo
2 days ago
- Yahoo
‘Ozempic for dogs' may be the next big thing in pet health
With the runaway success of drugs like Ozempic and Mounjaro effectively helping humans slim down, researchers and biotech firms are now sniffing out a new frontier: weight-loss drugs for dogs. With up to 60 per cent of dogs in the UK estimated to be overweight or obese, the market for such drugs could be considerable. Okava, a San Francisco-based bio-pharma company which specialises in pet health, is planning to run trials for a drug designed to mimic the effects of Ozempic, with the goal to produce an implant-version for dogs, which lasts six-months at a time. According to estimates on the company's website, the current market for such a product could be worth $10bn, and they hope to have a canine weight-loss drug available as early as 2028 or 2029. In human weight-loss drugs, the active ingredient in Mounjaro is called tirzepatide, and in Ozempic, it is semaglutide. Both work in similar ways, mimicking a natural hormone called GLP-1. This hormone regulates blood sugar and appetite, ultimately leading people to feel fuller longer and reducing food intake. The challenge for biotech firms is to reproduce that effect in dogs – a species well-known for practically limitless gorging. The hope is that an Ozempic-style drug may reduce dogs' begging behaviour, which many owners find it difficult to resist rewarding. Often, lack of appetite in dogs is associated with illness, meaning developing an effective drug that doesn't appear to make pets seem unwell is a fine balance. One such drug, named Slentrol, was launched in 2007, but did not sell well, partly due to how owners' perceived their pets behaviour when on the medication. Okava's planned implant, called OKV-119, contains a GLP-1 mimic called exenatide. Michael Klotsman, Okava's chief executive, said he hoped dogs' behavioural changes from OKV-119 would be quite different from illness-related appetite loss. 'What owners should expect to see is their pet eating appropriate portions without the previous food obsession – they'll still eat regularly and show interest in meals, just without the excessive begging, scavenging or gulping behaviour,' he told The Guardian. But not all tails are wagging. Vets have suggested that in most cases, dog owners would be better off avoiding obesity in their dogs through more exercise and by restricting their pets' diets. Caroline Allen, Chief Veterinary Officer at the RSPCA told The Independent: 'A healthy diet and exercise is the best way to keep our pets happy and well but we understand that owners can sometimes struggle to manage their pets' weight. There is currently little information about proposed weight-loss implants or vaccinations for animals, and owners shouldn't rely on them becoming available. 'Before resorting to these sorts of interventions, owners should seek help from their vet about how to reduce their pet's weight with a good diet and providing lots of opportunities to exercise and play in ways that their pet will enjoy." She added: 'It may be that weight loss jabs or implants may have a role to play in future in very limited circumstances where animals are clinically unwell, but the best thing we can do is set healthy habits from the start so our pets can live the best life possible.'